This content is funded by Boehringer Ingelheim International GmbH.
Please be advised that certain segments of the oral presentation have undergone necessary edits to adhere to contractual obligations. However, the complete presentation slides are available in the ‘Supplementary Materials’ section for your comprehensive review.
Experience a fresh take on cancer therapies as we bring you the latest symposium from the European Society for Medical Oncology’s (ESMO) Annual Meeting in Madrid, Spain. Leading experts in the field of lung cancer and sarcoma gathered for this enlightening session. The esteemed panel consisted of Patrick Schöffski, who serves as the Head of the Department of General Medical Oncology at the University Hospital Leuven in Belgium; Zofia Piotrowska, a Lung Cancer Medical Oncologist at Massachusetts General Hospital Cancer Center in Boston, USA; and Charles Rudin, Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York, USA.
Schöffski delivered an insightful overview of dedifferentiated liposarcoma and emphasised the potential of MDM2-p53 antagonism as a promising therapeutic approach. Piotrowska delved into the well-known biomarker HER2 (the presentation can be found in the supplementary materials section), while Rudin shed light on the appealing prospects of targeting DLL3 in both lung cancer and neuroendocrine carcinoma.
Supplementary Materials – please find the full presentation from ESMO 2023 here:
Piotrowska ESMO 2023 HER2
Rudin ESMO 2023 TCE
Schoffski ESMO 2023 MDM2-p53 in STS
